Literature DB >> 16799655

Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.

Moshira Mohamad Abd El-Wahed1.   

Abstract

BACKGROUND AND
PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma. However, there were very few published data regarding the role of maspin in ovarian carcinoma. The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study. They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm. However, all benign Brenner ovarian tumors were maspin positive. On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression. The two malignant Brenner tumors studied were maspin negative. There was a trend for maspin expression with high grade, high stage, bilateral tumors and tumors with metastasis. Tumors that showed maspin over-expression showed higher mitotic index (MI) (p=0.02). Invasive cancers were more likely to have predominantly cytoplasmic staining compared to LMP tumors.
CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters. These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies. Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16799655

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  5 in total

1.  Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma.

Authors:  Eun Ji Lee; Soo Jin Park; Cheol Lee; Ga Won Yim; Jae Weon Kim; Hee Seung Kim
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.

Authors:  Eiman Adel Hasby
Journal:  Tumour Biol       Date:  2015-11-03

3.  Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis.

Authors:  Zhiqiang Liu; Yangyang Shi; Wei Meng; Yufang Liu; Kaixuan Yang; Shuhua Wu; Zhilan Peng
Journal:  Arch Gynecol Obstet       Date:  2014-02       Impact factor: 2.344

4.  Maspin expression in prostate tumor elicits host anti-tumor immunity.

Authors:  Sijana H Dzinic; Kang Chen; Archana Thakur; Alexander Kaplun; R Daniel Bonfil; Xiaohua Li; Jason Liu; M Margarida Bernardo; Allen Saliganan; Jessica B Back; Hiroshi Yano; Dana L Schalk; Elyse N Tomaszewski; Ahmed S Beydoun; Gregory Dyson; Adelina Mujagic; David Krass; Ivory Dean; Qing-Sheng Mi; Elisabeth Heath; Wael Sakr; Lawrence G Lum; Shijie Sheng
Journal:  Oncotarget       Date:  2014-11-30

5.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.